| Titre : | Reactogenicity of Covid–19 Boosters : A Systematic Review and Meta Analysis |
| Auteurs : | Jhulia Anna Quitan ; Ecole des hautes études en santé publique (EHESP) (Rennes, FRA) |
| Type de document : | Mémoire |
| Année de publication : | 2025 |
| Description : | 43p. / ill. |
| Langues: | Anglais |
| Classement : | MPH/ (Mémoires MPH à partir de 2024) |
| Mots-clés : | Covid 19 ; Vaccin ; Vaccination ; Fièvre ; Effet secondaire ; Méta analyse |
| Résumé : |
Introduction: COVID-19 booster vaccines play a vital role in protecting against severe illness caused by SARS-CoV-2. However, concerns about side effects, especially fever, have reduced public willingness to receive booster doses. Fever is a common immune response after vaccination and is often used as a marker of vaccine reactogenicity. This study aimed to measure how often fever occurs after booster vaccination and to identify factors that affect this risk.
Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. Studies published between 2021 and 2025 were identified from PubMed, Embase, and Google Scholar. Eligible studies involved adults who received third or fourth doses of mRNA (Moderna, Pfizer), protein subunit (Novavax), or viral vector (AstraZeneca) vaccines. A random-effects meta-analysis was used to estimate pooled fever incidence. Meta-regression explored the effects of vaccine platform, dose schedule, booster type, and age group. Results: Fifteen RCTs including 3,548 participants were analyzed. The overall incidence of fever after booster vaccination was 7% (95% CI: 5%–11%). Fever was most common after Moderna Dose 3 and lowest after Novavax Dose 4. Meta-regression showed significantly reduced odds of fever with protein-based vaccines and fourth doses. No statistically significant differences were found for booster type (homologous vs. heterologous) or age group. Conclusion: This review shows that fever after COVID-19 booster vaccination is uncommon and varies by vaccine platform and dose number. Protein-based vaccines are associated with lower fever risk, making them suitable for populations sensitive to vaccine side effects. These findings can inform public health communication, guide vaccine policy, and support ongoing booster campaigns. Continued safety monitoring and updated evidence will be key to maintaining vaccine confidence. |
| Diplôme : | Master MPH of public health |
| Plan de classement simplifié : | Master of Public Health - master international de Santé Publique (MPH) |
| En ligne : | https://documentation.ehesp.fr/memoires/2025/mph/jhulia_anna_quitan.pdf |
Documents numériques (1)
Full ext URL |
